Emtricitabine rilpivirine tenofovir adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Created page with "==Adverse Reactions== ADVERSE REACTIONS The following adverse drug reactions are discussed in other sections of the labeling: * Lactic Acidosis/Severe Hepatomegaly with Stea..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Emtricitabine rilpivirine tenofovir}} | |||
{{CMG}}; {{AE}} {{MM}} | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
ADVERSE REACTIONS | ADVERSE REACTIONS | ||
Latest revision as of 05:03, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Adverse Reactions
ADVERSE REACTIONS
The following adverse drug reactions are discussed in other sections of the labeling:
- Lactic Acidosis/Severe Hepatomegaly with Steatosis [See Boxed Warning, Warnings and Precautions].
- Severe Acute Exacerbations of Hepatitis B [See Boxed Warning, Warnings and Precautions].
- New Onset or Worsening Renal Impairment [See Warnings and Precautions].
- Depressive Disorders [See Warnings and Precautions].
- Hepatotoxicity [See Warnings and Precautions].
- Bone Effects of Tenofovir DF [See Warnings and Precautions].
- Immune Reconstitution Syndrome [See Warnings and Precautions].[1]
References
Adapted from the FDA Package Insert.